Autobio Diagnostics Co

Autobio Diagnostics Co Tangible Book Value per Share

The Tangible Book Value per Share of Autobio Diagnostics Co (603658.SS) as of Oct 20, 2026 is 15.18 CNY. In the previous year, Tangible Book Value per Share was 14.41 CNY — a change of 5.36% (higher).

Tangible Book Value per Share

15.18CNY

YoY

5.36%

Last updated:

Tangible Book Value per Share of Autobio Diagnostics Co is 2025 15.18 CNY. Tangible Book Value per Share of Autobio Diagnostics Co was 2024 14.41 CNY. It decreases by 5.36% higher compared to the previous year.

The Autobio Diagnostics Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
2.69 CNY
Jan 1, 2019
3.66 CNY
Jan 1, 2020
10.50 CNY
Jan 1, 2021
11.93 CNY
Jan 1, 2022
12.85 CNY
Jan 1, 2023
14.20 CNY
Jan 1, 2024
14.41 CNY
Jan 1, 2025
15.18 CNY
The Autobio Diagnostics Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
15.18CNY+5.36%
14.41CNY+1.51%
14.20CNY+10.48%
12.85CNY+7.71%
11.93CNY+13.59%
10.50CNY+186.75%
3.66CNY+36.23%
2.69CNY+21.75%
2.21CNY-21.59%
2.82CNY+131.85%
1.21CNY+45.11%
0.84CNY-46.30%
1.56CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co., Ltd. generates revenue through the sale of in vitro diagnostic reagents and instruments, including gnostic products, microbiology detection products, and related devices. The company's immunodiagnostic products consist of microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. Microbiology detection products feature training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers, all distributed within domestic markets. The firm targets domestic healthcare providers and laboratories as primary buyers of its diagnostic reagents and instruments. Its core products serve clinical diagnostics needs for infectious disease testing, microbial identification, and immune response analysis. The company's product portfolio emphasizes domestic market distribution, with no mention of international sales channels or export activities. Autobio Diagnostics' revenue streams are derived from the manufacturing and distribution of diagnostic reagents, instruments, and related devices. The company focuses on domestic market penetration through its product range, which includes specialized reagents for microbiology and immunodiagnosis. No additional revenue sources such as service contracts or software licensing are indicated in the business description. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Tangible Book Value per Share of Autobio Diagnostics Co is 15.18 CNY in 2025.

Tangible Book Value per Share of Autobio Diagnostics Co changed from 14.41 CNY to 15.18 CNY, representing a 5.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Autobio Diagnostics Co

All Key Metrics — Autobio Diagnostics Co